Epidemiology & Biostatistics // Biostatistics

Rachel Jia, MS

Research Biostatistician
Office Phone:
646-735-8057
Education:
University of Michigan

Current Research Interests

Since joining MSKCC, Rachel Jia works closely with Dr. Glenn Heller in collaboration with physicians from Genitourinary Oncology Service to characterize the association between the novel prognostic marker circulating tumor cells with patient survival among metastatic castration-resistant prostate cancer patients. She also works with Dr. Ethan Basch in Health Outcomes to compare the patient self-report and clinician report on adverse symptom events and examine their associations with various end points. Ms. Jia also works with Dr. Li-Xuan Qin to develop a competing-risk nomogram for predicting local recurrence among soft tissue sarcoma patients using a retrospectively identified patient population, and is currently working towards validating the nomogram on an external clinical trial data set. In addition, she was also involved in several expression array data analysis projects to identify the gene profiling in breast cancer and gastric cancer. Ms. Jia recently started a project with Dr. Mithat Gonen to develop methods for evaluating recurrence free survival as a surrogate endpoint for overall survival among late stage colorectal cancer patients.

Publications by Rachel Jia

Selected Publications

  1. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordguist LT, Venner PM, Heidenreich A, Chu L, Heller G. Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 2011 Apr 11. [Epub ahead of print]
  2. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Isonos A, Culkin A, Kris MG, Schrag D. Adverse Symptom Event Reporting by Patients versus Clinicians: Relationships with Clinical Outcomes. Journal of National Cancer Institution. 2009 Dec 2; 101(23):1624-32. Epub 2009 Nov 17.
  3. Scher HI, Jia X, DeBono JS, Fleisher M, Peinta KJ, Raghavan D, Heller G. Circulating Tumor Cell Number as a Prognostic Marker in Progressive Castration-Resistant Prostate Cancer: a reanalysis of IMMC38 trial data. The Lancet Oncology. 2009 Mar; 10(3): 233-9.
  4. Moskowitz CS, Jia X, Schwartz LH, Gonen M. A Simulation Study to Evaluate the Impact of the Number of Lesions Measured on Response Assessment. European Journal of Cancer. 2009 Jan;45(2):300-10.
  5. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I Study of Samarium-153 Lexidronam with Docetaxel in Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology. 2009 May 20;27(15):2436-42.